Drug Profile
Epoetin alfa biosimilar - Amega Bitoech
Alternative Names: Recombinant erythropoietin - Amega BiotechLatest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Amega Biotech
- Class Antianaemics; Recombinant erythropoietins
- Mechanism of Action Erythropoiesis stimulants; Erythropoietin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase Unknown Anaemia
Most Recent Events
- 19 Aug 2013 Investigation in Anaemia in Argentina (Parenteral)